You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

annual relapse rate

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Neuromyelitis Optica Spectrum Disorder Trial in Isfahan (Azathioprine, Rituximab)

Completed
Has Results
  • Neuromyelitis Optica Spectrum Disorder
  • Isfahan, Iran, Islamic Republic of
    Kashani Hospital
Sep 29, 2020

Patients With Schizophrenia Trial (Therapeutic Drug Monitoring (TDM) and Pharmacogenetics (PG))

Not yet recruiting
  • Patients With Schizophrenia
  • Therapeutic Drug Monitoring (TDM) and Pharmacogenetics (PG)
  • (no location specified)
May 1, 2023

Asthma Trial in Paris (2: Intervention, 1: Control)

Completed
  • Asthma
  • 2: Intervention
  • 1: Control
  • Paris, France
    Service des Urgences, Hôpital Lariboisière
Mar 9, 2022

Mass Accumulation Rate asPredictive Biomarker in Multiple

Recruiting
  • Multiple Myeloma in Relapse
    • Duarte, California
    • +5 more
    Jul 13, 2022

    Relapsing Remitting Multiple Sclerosis (RRMS) Trial in Tehran (Pegylated interferon beta-1a, Interferon Beta-1A Prefilled

    Active, not recruiting
    • Relapsing Remitting Multiple Sclerosis (RRMS)
    • Pegylated interferon beta-1a
    • Interferon Beta-1A Prefilled Syringe
    • Tehran, Iran, Islamic Republic of
      Sina Hospital
    Feb 5, 2022

    Disease in Medium Term of Implementation ofSystem of Extended

    Recruiting
    • Eating Disorders
    • +2 more
    • semi-standardized interview
    • care experience questionary
    • Saint-etienne, France
      CHU de SAINT-ETIENNE
    Sep 12, 2022

    Biochemical Relapse Free Survival, Complications Rates (Erectile Dysfunction, GI, GU Complications) Trial in St Petersburg

    Recruiting
    • Biochemical Relapse Free Survival
    • Complications Rates (Erectile Dysfunction, GI, GU Complications)
    • Stereotactic ablative radiotherapy
    • High dose rate brachytherapy
    • St Petersburg, Russian Federation
      Sergey Novikov
    Apr 28, 2021

    Steroid-Sensitive Nephrotic Syndrome Trial in Islamabad (Prednisolone)

    Recruiting
    • Steroid-Sensitive Nephrotic Syndrome
    • Islamabad, Capital, Pakistan
      Pakistan Institute of Medical Sciences
    May 9, 2021

    A Study for Tysabri Participant Preference

    Recruiting
    • Relapsing-Remitting Multiple Sclerosis (RRMS)
    • Augsburg, Germany
    • +39 more
    Mar 22, 2022

    Multiple Myeloma in Relapse Trial in Canada (Daratumumab)

    Completed
    • Multiple Myeloma in Relapse
    • Kingston, Ontario, Canada
    • +5 more
    Feb 14, 2022

    Biochemical Relapse Fo Malignant Tumor of Prostate Trial in Taipei (18F-FACBC PET/CT)

    Recruiting
    • Biochemical Relapse Fo Malignant Neoplasm of Prostate
    • 18F-FACBC PET/CT
    • Taipei, Taiwan
      National Taiwan University Hospital
    Sep 8, 2021

    Myopia Trial in Ho Chi Minh City (BHVI1 eye drops, BHVI2 eye drops, BHVI3 eye drops)

    Active, not recruiting
    • Myopia
    • BHVI1 eye drops
    • +2 more
    • Ho Chi Minh City, Vietnam
      Department of Ophthalmology - An Sinh Hospital
    Aug 23, 2021

    Brain Metastases, Small Cell Lung Cancer Trial in Birmingham (NovoTTF-200A, Stereotactic Radiosurgery (SRS))

    Terminated
    • Brain Metastases
    • Small Cell Lung Cancer
    • NovoTTF-200A
    • Stereotactic Radiosurgery (SRS)
    • Birmingham, Alabama
      University of Alabama at Birmingham (UAB), Hazelrig-Salter Radia
    Feb 17, 2022

    Copaxone Subcutaneous Injection Syringe Special Drug Use-Result

    Recruiting
    • Multiple Sclerosis
    • Glatiramer acetate
    • Tokyo, Japan
      Takeda selected site
    Jan 12, 2022

    Multiple Sclerosis, Relapsing-Remitting Trial in Hamburg (web-based intervention programme, web-based information material

    Active, not recruiting
    • Multiple Sclerosis, Relapsing-Remitting
    • web-based intervention programme
    • web-based information material offered via the same platform (broca®) in addition to usual care
    • Hamburg, Germany
      Universitätsklinikum Hamburg-Eppendorf
    Jun 21, 2022

    Relapse Rate After Allo-HSCT Trial in Shanghai (Flu-Bu-Mel)

    Active, not recruiting
    • Relapse Rate After Allo-HSCT
    • Shanghai, China
    • +1 more
    Jun 1, 2021

    Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Secondary Progressive Trial in Tokyo (OCH-NCNP1, Placebo)

    Active, not recruiting
    • Multiple Sclerosis, Relapsing-Remitting
    • Multiple Sclerosis, Secondary Progressive
    • Tokyo, Japan
      National Center of Neurology and Psychiatry
    Sep 28, 2022

    Inebilizumab and Rituximab in Neuromyelitis Optica Spectrum

    Not yet recruiting
    • Neuromyelitis Optica Spectrum Disorders
    • (no location specified)
    Sep 29, 2023

    Smoking, Abdominal Aortic Aneurysm, IQOS Use Trial in Atsugi (IQOS, Cigarette, Smoking Cessation)

    Active, not recruiting
    • Smoking
    • +2 more
    • IQOS
    • +2 more
    • Atsugi, Kanagawa Prefecture, Japan
      Atsugi City Hospital
    Dec 13, 2022

    Multiple Sclerosis Trial in Worldwide (Ofatumumab, First line DMT)

    Recruiting
    • Multiple Sclerosis
    • Bayonne, Bayonne Cedex, France
    • +42 more
    Jul 25, 2022

    Chronic Pulmonary Aspergillosis Trial in Chandigarh (Itraconazole 200 mg, Voriconazole 200mg)

    Recruiting
    • Chronic Pulmonary Aspergillosis
    • Itraconazole 200 mg
    • Voriconazole 200mg
    • Chandigarh, India
    • +1 more
    Jun 10, 2022

    Obesity Trial in Châteauroux (Quarterly remote motivational interviews)

    Not yet recruiting
    • Obesity
    • Quarterly remote motivational interviews
    • Châteauroux, France
      Clinique Saint-François
    Jul 24, 2023

    Relapse Trial in Aarhus, Oslo (Bonding of either CAD/CAM or conventional multistranded stainless steel fixed retainer)

    Active, not recruiting
    • Relapse
    • Bonding of either CAD/CAM or conventional multistranded stainless steel fixed retainer
    • Aarhus, Denmark
    • +1 more
    Dec 17, 2020

    Multiple Sclerosis Trial in France (DMT withdrawal, DMT continuation)

    Recruiting
    • Multiple Sclerosis
    • DMT withdrawal
    • DMT continuation
    • Angers, France
    • +22 more
    Mar 25, 2022

    Acquired Hemophilia Trial in Tianjin (Daratumumab)

    Recruiting
    • Acquired Hemophilia
    • Tianjin, China
      Chinese Academy of Medical Science and Blood Disease Hospital
    May 5, 2023